Skip to main content
Erschienen in: Aesthetic Plastic Surgery 4/2011

01.08.2011 | Original Article

Mandible Changes Evaluated by Computed Tomography Following Botulinum Toxin A Injections in Square-faced Patients

verfasst von: C. S. Chang, L. Bergeron, C. C. Yu, P. K. T. Chen, Y. R. Chen

Erschienen in: Aesthetic Plastic Surgery | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

A facial contour that is oval is more pleasing in Asian women. Patients with a square face often seek facial contouring procedures to improve their appearance. Treatment often involves various combinations of Botulinum NeuroToxin A (BoNTA) injections into the masseters and/or mandibular angle resection. Many physicians claim that muscle paralysis with injections alone will decrease pulling on the underlying bone and also treat underlying bony flaring when present. Muscular changes after BoNTA injections have been well documented. However, the effect of BoNTA injections on the underlying mandibular bone morphology has not been studied to the best of the authors’ knowledge. The goal of this study was to determine whether there are mandibular changes after masseter injection with botulinum toxin.

Methods

In this retrospective study of ten female patients seeking treatment for a square face, three-dimensional CT scans were taken before and 3 months after standardized BoNTA injections in bilateral masseters. Mandibular cortex thickness, mandibular bone thickness, and mandibular volume were measured.

Results

Soft-tissue changes were observed but no bony changes were observed 3 months after injections.

Conclusions

In this study of adult patients, there were no statistically significant mandibular changes 3 months after BoNTA injection. The current theory of mandibular flaring resolution after partial muscle paralysis is not supported by our findings. Therefore, a patient presenting both masseteric hypertrophy and bony flaring will most likely require a combined muscular and bony procedure.
Literatur
1.
Zurück zum Zitat Yu CC, Chen PK, Chen YR (2007) Botulinum toxin A for lower facial contouring: a prospective study. Aesth Plast Surg 31:445–451; discussion 452–443 Yu CC, Chen PK, Chen YR (2007) Botulinum toxin A for lower facial contouring: a prospective study. Aesth Plast Surg 31:445–451; discussion 452–443
2.
Zurück zum Zitat Kim YH, Cho BC, Lo LJ (2009) Facial contouring surgery for Asians. Semin Plast Surg 23:22–31PubMedCrossRef Kim YH, Cho BC, Lo LJ (2009) Facial contouring surgery for Asians. Semin Plast Surg 23:22–31PubMedCrossRef
3.
Zurück zum Zitat Masters F, Georgiade N, Pickrell K (1955) The surgical treatment of benign masseteric hypertrophy. Plast Reconstr Surg (1946) 15:215–221CrossRef Masters F, Georgiade N, Pickrell K (1955) The surgical treatment of benign masseteric hypertrophy. Plast Reconstr Surg (1946) 15:215–221CrossRef
4.
Zurück zum Zitat von Lindern JJ, Niederhagen B, Appel T, Bergé S, Reich RH (2001) Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment. Plast Reconstr Surg 107:327–332CrossRef von Lindern JJ, Niederhagen B, Appel T, Bergé S, Reich RH (2001) Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment. Plast Reconstr Surg 107:327–332CrossRef
5.
Zurück zum Zitat Lee CJ, Kim SG, Kim YJ, Han JY, Choi SH, Lee SI (2007) Electrophysiologic change and facial contour following botulinum toxin A injection in square faces. Plast Reconstr Surg 120:769–778PubMedCrossRef Lee CJ, Kim SG, Kim YJ, Han JY, Choi SH, Lee SI (2007) Electrophysiologic change and facial contour following botulinum toxin A injection in square faces. Plast Reconstr Surg 120:769–778PubMedCrossRef
6.
Zurück zum Zitat Castro WH, Gomez RS, da Silva Oliveira J, Moura MD, Gomez RS (2005) Botulinum toxin type A in the management of masseter muscle hypertrophy. J Oral Maxillofac Surg 63:20–24PubMedCrossRef Castro WH, Gomez RS, da Silva Oliveira J, Moura MD, Gomez RS (2005) Botulinum toxin type A in the management of masseter muscle hypertrophy. J Oral Maxillofac Surg 63:20–24PubMedCrossRef
7.
Zurück zum Zitat To EW, Ahuja AT, Ho WS, King WW, Wong WK, Pang PC, Hui AC (2001) A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br J Plast Surg 54:197–200PubMedCrossRef To EW, Ahuja AT, Ho WS, King WW, Wong WK, Pang PC, Hui AC (2001) A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br J Plast Surg 54:197–200PubMedCrossRef
8.
Zurück zum Zitat Choe SW, Cho WI, Lee CK, Seo SJ (2005) Effects of botulinum toxin type A on contouring of the lower face. Dermatol Surg 31:502–507; discussion 507–508 Choe SW, Cho WI, Lee CK, Seo SJ (2005) Effects of botulinum toxin type A on contouring of the lower face. Dermatol Surg 31:502–507; discussion 507–508
9.
Zurück zum Zitat Kim HJ, Yum KW, Lee SS, Heo MS, Seo K (2003) Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg 29:484–489PubMedCrossRef Kim HJ, Yum KW, Lee SS, Heo MS, Seo K (2003) Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg 29:484–489PubMedCrossRef
10.
Zurück zum Zitat Kim JH, Shin JH, Kim ST, Kim CY (2007) Effects of two different units of botulinum toxin type A evaluated by computed tomography and electromyographic measurements of human masseter muscle. Plast Reconstr Surg 119:711–717PubMedCrossRef Kim JH, Shin JH, Kim ST, Kim CY (2007) Effects of two different units of botulinum toxin type A evaluated by computed tomography and electromyographic measurements of human masseter muscle. Plast Reconstr Surg 119:711–717PubMedCrossRef
11.
Zurück zum Zitat Park MY, Ahn KY, Jung DS (2003) Botulinum toxin type A treatment for contouring of the lower face. Dermatol Surg 29:477–483; discussion 483 Park MY, Ahn KY, Jung DS (2003) Botulinum toxin type A treatment for contouring of the lower face. Dermatol Surg 29:477–483; discussion 483
12.
Zurück zum Zitat Ahn KY, Kim ST (2007) The change of maximum bite force after botulinum toxin type A injection for treating masseteric hypertrophy. Plast Reconstr Surg 120:1662–1666PubMedCrossRef Ahn KY, Kim ST (2007) The change of maximum bite force after botulinum toxin type A injection for treating masseteric hypertrophy. Plast Reconstr Surg 120:1662–1666PubMedCrossRef
13.
Zurück zum Zitat Matic DB, Yazdani A, Wells RG, Lee TY, Gan BS (2007) The effects of masseter muscle paralysis on facial bone growth. J Surg Res 139:243–252PubMedCrossRef Matic DB, Yazdani A, Wells RG, Lee TY, Gan BS (2007) The effects of masseter muscle paralysis on facial bone growth. J Surg Res 139:243–252PubMedCrossRef
14.
Zurück zum Zitat Bouvier M, Hylander WL (1984) The effect of dietary consistency on gross and histologic morphology in the craniofacial region of young rats. Am J Anat 170:117–126PubMedCrossRef Bouvier M, Hylander WL (1984) The effect of dietary consistency on gross and histologic morphology in the craniofacial region of young rats. Am J Anat 170:117–126PubMedCrossRef
15.
Zurück zum Zitat Bresin A, Kiliaridis S, Strid KG (1999) Effect of masticatory function on the internal bone structure in the mandible of the growing rat. Eur J Oral Sci 107:35–44PubMedCrossRef Bresin A, Kiliaridis S, Strid KG (1999) Effect of masticatory function on the internal bone structure in the mandible of the growing rat. Eur J Oral Sci 107:35–44PubMedCrossRef
Metadaten
Titel
Mandible Changes Evaluated by Computed Tomography Following Botulinum Toxin A Injections in Square-faced Patients
verfasst von
C. S. Chang
L. Bergeron
C. C. Yu
P. K. T. Chen
Y. R. Chen
Publikationsdatum
01.08.2011
Verlag
Springer-Verlag
Erschienen in
Aesthetic Plastic Surgery / Ausgabe 4/2011
Print ISSN: 0364-216X
Elektronische ISSN: 1432-5241
DOI
https://doi.org/10.1007/s00266-010-9624-5

Weitere Artikel der Ausgabe 4/2011

Aesthetic Plastic Surgery 4/2011 Zur Ausgabe

Announcements

Announcements

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.